# Neuraxis, INC > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Neuraxis, INC). ## Overview Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients. Its product portfolio includes the IB-Stim device for functional abdominal pain associated with IBS in children and the RED device for identifying chronic constipation due to pelvic floor dyssynergia in adults. ## Products & services • IB-Stim neuromodulation device for pediatric IBS pain • RED point-of-care test for pelvic floor dyssynergia • FDA-cleared devices for specific gastrointestinal indications • Development pipeline for additional pediatric and adult indications - **IB-Stim device** (70%) — PENFS neuromodulation therapy used for children and adolescents with functional abdominal pain associated with IBS. - **RED device** (25%) — Office-based diagnostic device used to identify chronic constipation due to pelvic floor dyssynergia in adults. - **Other indications and pipeline** (5%) — Development-stage uses and future indications for the company's neuromodulation platform. - IB-Stim neuromodulation device for pediatric IBS pain - RED point-of-care test for pelvic floor dyssynergia - FDA-cleared devices for specific gastrointestinal indications - Development pipeline for additional pediatric and adult indications ## Customers The company sells primarily to healthcare companies, especially hospitals and clinics that purchase devices on a purchase-order basis. Its end users are patients treated for functional abdominal pain, IBS-related symptoms, and constipation-related disorders, with reimbursement coverage playing a central role in adoption. The business also serves lower-income patients through discounting and financial assistance programs when insurance coverage is unavailable. - **Hospitals and clinics** (primary) — Primary buyers of IB-Stim devices for treating pediatric functional abdominal pain and related conditions. - **Healthcare companies and provider organizations** (primary) — Purchasers that place purchase orders and integrate the devices into clinical workflows. - **Commercial insurers and reimbursed patients** (primary) — Not direct buyers, but critical to adoption because coverage determines patient access and volume. - **Adult GI practices** (secondary) — Users of RED for point-of-care identification of pelvic floor dyssynergia in constipation patients. - **Self-pay and financially assisted patients** (secondary) — Patients receiving discounted devices when insurance coverage is unavailable. - Hospitals and clinics purchasing IB-Stim for patient treatment - Healthcare providers using RED in office-based evaluation workflows - Insured patients whose treatment is reimbursed by commercial payers - Uninsured or underinsured patients served through discount programs - Future indication customers in pediatric and adult GI care ## Geography Neuraxis is headquartered in the United States and appears to operate primarily in the U.S. healthcare market. Its commercial exposure is tied to domestic reimbursement, FDA clearance, and adoption by U.S. hospitals, clinics, and insurers rather than to a broad international footprint. - Headquartered in the United States - Commercial activity centered on U.S. hospitals and clinics - Reimbursement depends on U.S. commercial insurance coverage - FDA regulatory pathway is central to U.S. market expansion ## Strategy The company’s strategy is to expand insurance coverage for IB-Stim, which it describes as the main driver of customer adoption and revenue. It is also pursuing FDA clearance for additional indications and expanding adoption of RED, while continuing product development and commercialization efforts. - **Broaden insurance coverage for IB-Stim** (short-term) — Coverage determines patient access and is the main driver of device adoption and revenue. - **Obtain FDA clearance for new indications** (medium-term) — Additional indications can expand the addressable market and increase device usage per patient. - **Expand RED adoption** (medium-term) — RED adds a second commercial product and broadens the company beyond a single indication. - Expand commercial insurance coverage for IB-Stim - Grow sales through hospitals, clinics, and purchase-order channels - Advance FDA clearance for additional indications - Broaden adoption of RED in adult constipation workflows - Support commercialization with ongoing R&D and sales efforts ## Risks The business depends on reimbursement adoption, regulatory clearance, and successful commercialization of a narrow product set, so delays in any of these areas can materially affect growth. It also faces going-concern, internal control, and execution risks typical of early-stage medical device companies that rely on external financing and continued clinical/regulatory progress. - **Insurance reimbursement dependence** [high] — Commercial adoption is tied to insurer coverage, so slow payer acceptance can limit patient access and sales volume. - **Regulatory approval risk** [high] — Future growth depends on FDA clearance for additional indications and product uses. - **Going-concern and financing risk** [critical] — The company has required external capital to fund operations and commercialization efforts. - **Product concentration** [high] — Revenue is concentrated in a small number of devices and indications, increasing sensitivity to adoption changes. - **Internal control and reporting risk** [medium] — Reported material weaknesses and prior restatement increase the risk of financial reporting errors. - Insurance coverage adoption is the key demand driver for IB-Stim - FDA clearance risk for new indications could delay market expansion - Single-product concentration increases dependence on IB-Stim - Going-concern risk reflects ongoing operating losses and financing needs - Internal control weaknesses can affect reporting reliability and compliance ## Accounting Revenue recognition is driven by purchase orders and standard terms, so timing depends on when devices are shipped and accepted under customer agreements. Investors should also watch estimates around inventory obsolescence, fair value changes in warrant liabilities, and the impact of internal control weaknesses and prior restatements on reported results. - **Revenue recognition on device shipments** — Net sales timing - **Patient discounting and assistance programs** — Net sales and gross margin - **Inventory expiration and obsolescence** — Cost of goods sold - **Warrant liability fair value** — Other income/expense - **Internal control remediation and restatement risk** — Financial statement reliability - Revenue recognized on purchase-order based device sales - Discounts to uninsured patients affect net sales and mix - Inventory expiration and obsolescence can affect cost of goods sold - Warrant liability fair value can create non-cash earnings volatility - Material weaknesses raise risk of restatement or timing errors --- *Last updated: 2026-04-29T04:41:16.627786+00:00*